Conference call to be held Monday, November 4, 2024, at 8:30 AM ET
NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday November 4, 2024, at 8:30 AM ET to discuss results for the third quarter of 2024 and provide a business outlook for the remainder of the year. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline of investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
Humana introduces Agent Assist to help member advocates deliver faster, more personalized support, enabled by…
CINCINNATI, Feb. 3, 2026 /PRNewswire/ -- AssureCare® LLC, a leading healthcare technology company delivering an…
Doxim's Utility Payments Team will drive seamless, omnichannel billing-to-payments solutions for utilities to bridge the…
BOULDER, Colo., Feb. 3, 2026 /PRNewswire/ -- Amplifire, the leading adaptive learning platform built on patented…
LOUISVILLE, Ky., Feb. 3, 2026 /PRNewswire/ -- Cognision today unveiled Cognision360™, a groundbreaking web-based platform that consolidates…
SUMMIT, N.J. and BOSTON, Feb. 3, 2026 /PRNewswire/ -- BEESY, LLC ("BEESY") a leading AI-enabled…